drugset / Trial / NCT03419650

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650

NaSingle-groupOpen-labelTreatment

Summary

Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.

Timeline

Start
2018-07-20
Primary completion
2021-08-25
Completion
2021-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 40 iu

Indications